Evaluation of a New Cephalosporin Antibiotic, Cephapirin
- 1 April 1972
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 1 (4) , 303-309
- https://doi.org/10.1128/aac.1.4.303
Abstract
Cephapirin sodium, a parenterally administered derivative of cephalosporanic acid, was tested in vitro against 150 stock cultures of Enterobacteriaceae and 30 stock cultures each of Pseudomonas aeruginosa and Staphylococcus aureus . Both broth- and agar-dilution techniques were employed with two sizes of inocula of organisms. At a concentration of 7.5 μg or less/ml, cephapirin inhibited and killed 100% of strains of Escherichia coli and Proteus mirabilis and more than 80% of Klebsiella species when tested against an inoculum of 10 5 bacterial cells/ml. However, even at 100 μg/ml, only a few isolates of other Enterobacteriaceae and Pseudomonas were inhibited. A 100-fold increase in the inoculum resulted in decreased susceptibility of organisms. All penicillin-susceptible as well as penicillin-resistant S. aureus isolates were inhibited and killed by 5 μg or less of cephapirin/ml when tested with an inoculum of either 10 4 or 10 6 organisms/ml. The drug also was studied in various doses in the treatment of 77 patients with diverse infections. Cephapirin was effective in the treatment of 27 of 32 patients with pulmonary infection, as well as in 6 of 7 patients with staphylococcal or streptococcal soft tissue infection. Of 25 patients with urinary-tract infections, 19 developed a negative culture during therapy. A single 4-g intramuscular dose of cephapirin was effective in only 2 of 11 patients with gonococcal urethritis or endocervicitis. Two patients with gonococcal urethritis treated with multiple injections were cured. The drug was well tolerated except for pain at the site of injection in 14 patients and phlebitis in 4 patients. No abnormalities in renal or hepatic function could be attributed to cephapirin. In addition, no abnormalities were found in the renal tubules of rabbits challenged with 500 mg of cephapirin/kg. If further studies document that cephapirin is well tolerated by the parenteral route, it may have advantages over cephalothin or cephaloridine.Keywords
This publication has 11 references indexed in Scilit:
- Laboratory and pharmacologic studies of BL-P-1322 (cephapirin sodium) in children.1971
- Nephrotoxicity due to Cephaloridine: A Light- and Electron-Microscopic Study in RabbitsThe Journal of Infectious Diseases, 1970
- Laboratory studies with a new cephalosporanic acid derivative.1969
- In vitro and in vivo evaluation of cephalexin.1968
- New cephalosporin antibiotic--cephaloridine. Clinical and laboratory evaluationArchives of internal medicine (1960), 1967
- A Critical Evaluation of Nalidixic Acid in Urinary-Tract InfectionsNew England Journal of Medicine, 1966
- Factors influencing in vitro susceptibility to the cephalosporins and clinical trial of an oral cephalosporin, cephaloglycin.1966
- Laboratory and Clinical Evaluation of a New Antibiotic—CephalothinAnnals of Internal Medicine, 1965
- Factors Determining the Outcome of Chemotherapy in Infections of the Urinary TractAnnals of Internal Medicine, 1963
- Comparison of Single-disc and Tube-dilution Techniques in Determining Antibiotic Sensitivities of Gram-negative PathogensAnnals of Internal Medicine, 1963